



12780 El Camino Real, San Diego, CA 92130 (858) 617-7600

June 15, 2021

Dear Vermont Attorney General's Office,

As required by 18 V.S.A. § 4637(c), Neurocrine Biosciences, Inc. is providing a follow up to the 3-day Initial Notice Report sent on June 3, 2021. Please find the New Drug Report for the product below:

Product Name: INGREZZA[®] (valbenazine) 60 mg capsules
NDC: 70370-1060-01

(1) A description of the marketing and pricing plans used in the launch of the new drug in the United States and internationally – We determine the price of our medicines based on their value and impact to patients, families, care partners, providers, insurers and society. In so doing, we adhere to the highest ethical and compliance standards and are guided by the following principles:

- Improving the lives and well-being of patients
- Maximizing access and reducing out-of-pocket costs for eligible patients
- Striving to reduce obstacles for patients to fill a prescription or undergo treatment
- Fueling the discovery and development of life-changing medicines

Specific marketing and pricing plans for this new indication are not publicly available therefore, Neurocrine Biosciences, Inc. is limiting its response to this item pursuant to 18 V.S.A. § 4637(d).

(2) The estimated volume of patients who may be prescribed the drug – not publicly available

(3) Whether the drug was granted breakthrough therapy designation or priority review by the FDA prior to final approval – Breakthrough Therapy = yes, Priority Review = no

(4) The date and price of acquisition if the drug was not developed by the manufacturer – N/A

Please let me know if additional information is needed at this time.

Sincerely,

Ingrid M. Brewer

Ingrid M. Brewer
Sr. Manager, Contracts, Pricing & Trade
Neurocrine Biosciences, Inc.